Compare · PRCT vs RMD
PRCT vs RMD
Side-by-side comparison of PROCEPT BioRobotics Corporation (PRCT) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRCT and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.00B, about 25.5x PRCT ($1.10B).
- Over the past year, PRCT is down 66.7% and RMD is down 23.4% - RMD leads by 43.4 points.
- RMD has been more active in the news (6 items in the past 4 weeks vs 3 for PRCT).
- Both have 25 recent analyst ratings on file.
- Company
- PROCEPT BioRobotics Corporation
- ResMed Inc.
- Price
- $19.30-9.07%
- $193.27-2.64%
- Market cap
- $1.10B
- $28.00B
- 1M return
- -30.29%
- +0.56%
- 1Y return
- -66.73%
- -23.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 25
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PRCT
- PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
- PROCEPT BioRobotics downgraded by Truist with a new price target
- Evercore ISI initiated coverage on PROCEPT BioRobotics with a new price target
- PROCEPT BioRobotics downgraded by Leerink Partners with a new price target
- Director Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)
- Director Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)
- Director Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)
- Director Harris Taylor C. was granted 3,315 shares, increasing direct ownership by 3% to 102,491 units (SEC Form 4)
- Director Little Elisabeth Sandoval was granted 3,315 shares, increasing direct ownership by 26% to 15,876 units (SEC Form 4)
- Director Moll Frederic H was granted 3,315 shares, increasing direct ownership by 0.38% to 866,474 units (SEC Form 4)
Latest RMD
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million